Abstract 5172
Background
The aim of the present study was to investigate predictors of survival in a cohort of patients with incurable cancer. This may highlight areas of care which can be addressed to optimise outcomes.
Methods
Patient demographics, performance status (ECOG), inflammatory markers (modified Glasgow Performance Score (mGPS)), and nutritional parameters [BMI, % weight loss (WL)] were recorded. Baseline body composition were examined using computed tomography (CT) images. Sarcopenia and low muscle attenuation (MA) were defined using published cut-offs. Cancer cachexia (CC) was defined using the consensus definition (2011). Cox models were used to estimate mortality hazard ratios, adjusted for known prognostic covariates – age, sex & site.
Results
In total, 1027 patients were recruited (51% male, median age 66 years). Gastrointestinal cancer was most common (40%) and metastatic disease was present in 87% of patients. In total, 86% were on active chemotherapy treatment. On multivariate analysis, primary site, ECOG-PS, WL and mGPS predicted survival. Lung and GI cancer patients had higher risk of death compared to other tumour groups [HR:1.769 (95% CI:1.305–2.398), p < 0.001 and HR:1.576 (95% CI:1.211–2.053), p = 0.001, respectively]. mGPS score of 1 or 2 were associated with increased risk of death versus mGPS of 0 [HR:1.399 (95% CI:1.024–1.910), p = 0.035 & HR:1.831 (95% CI:1.442–2.324), p < 0.001, respectively]. WL > 10% in the preceding 3 months was associated with reduced survival [HR:2.501 (95% CI:1.425–4.389), p = 0.001]. Sarcopenia, CC and low MA were significant predictors of survival on univariate analysis, but not on multivariate analysis.
Conclusions
Independent predictors of survival in this cohort of advanced cancer patients were cancer site, ECOG, WL > 10% and mGPS, the latter two being important components of the cancer cachexia syndrome. Attenuation of weight loss and inflammation may improve outcomes for patients undergoing palliative treatment for cancer.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract